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INTRODUCTION
The major clinical manifestations of chronic graft-versus-
host disease (GVHD) are dermatitis, keratoconjunctivitis,
oral mucositis, generalized sicca syndrome, and hepatic dys-
function. The disease has clinicopathological findings
resembling those of autoimmune disorders [1,2]. In severe
disease, malabsorption, esophageal and vaginal strictures,
and pulmonary insufficiency may develop [3]. Chronic
GVHD is associated with prolonged immunodeficiency,
which is a predisposing factor for recurrent and sometimes
fatal infection [4]. Chronic GVHD affects approximately
30% to 70% of long-term survivors and is therefore an
important clinical problem after hematopoietic stem cell
transplantation (HSCT) [3,5-7].
It is well known that both acute and chronic GVHD are
accompanied by a graft-versus-leukemia (GVL) effect [8-10].
This effect is probably greater in chronic than in acute
GVHD [9-10]. Many studies have shown that leukemic
patients with chronic GVHD have a lower incidence of
relapse and better disease-free survival than do those without
chronic GVHD [8-10]. However, the presence of moderate-
to-severe chronic GVHD also implies a substantially
increased immunosuppressive state, which leads to higher
risk of infection and reduced function of affected organs.
These states lead to higher morbidity and mortality rates
among patients with moderate-to-severe chronic GVHD.
Patients with mild chronic GVHD need only minimal, if
any, immunosuppressive treatment, whereas those with
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ABSTRACT
Among 810 consecutive hematopoietic stem cell transplantation (HSCT) patients, 679 survived more than 3 months
and were evaluated for chronic GVHD. The aim of this study was to find predisposing factors increasing the risk of
development of moderate-to-severe chronic GVHD. Many of the donors were HLA-identical siblings or related (n =
435), 185 were HLA-matched unrelated, and 59 were mismatched related or unrelated donors. Most of the patients had
a hematological malignancy (n = 568), but 111 patients with a nonmalignant disease were included. Two hundred
twenty-three patients (33%) developed mild, 41 (6%) moderate, and 15 (2.2%) severe chronic GVHD. The 5-year
probability of development of moderate-to-severe chronic GVHD was 10%. We analyzed 30 potential risk factors for
chronic GVHD. In the multivariate analysis, acute GVHD grades II to IV (relative hazard [RH], 2.30; 95% CI, 1.29-
4.10; P = .005), CML diagnosis (RH, 2.37; CI, 1.38-4.08; P = .002) and transplantation from an immunized female donor
to a male recipient (RH, 2.16; CI, 1.14-4.11; P = .02) were independent risk factors for moderate-to-severe chronic
GVHD. Recipient age also was significant (RH, 2.42; CI, 1.23-4.77; P = .01) if CML was not included in the analysis. In
patients with no risk factors, the 5-year probability of development of moderate-to-severe chronic GVHD was 5%. In
patients with 1 risk factor, the probability was 13%; 2 risk factors, 23%; and 3 risk factors, 45%. Among patients who
developed chronic GVHD (n = 279), acute GVHD grades II to IV (RH, 2.18; CI, 1.23-3.86; P < .01) was the only pre-
dictive factor for moderate-to-severe chronic GVHD versus mild disease. Patients with previous acute GVHD grades II
to IV may benefit from more aggressive initial treatment. This possibility would have to be examined in clinical trials.
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more severe forms need more aggressive and prolonged
treatment. Antithymocyte globulin (ATG), total lymphoid
irradiation (TLI), thalidomide [11], and, more recently,
extracorporeal psoralen and UV-A radiation (PUVA) [12]
are used to treat more severe forms of chronic GVHD.
Chronic GVHD usually is classiﬁed with a 2-grade scale:
limited or extensive [13]. In new studies a 3-grade scale has
been evaluated in which the treating physician, taking the
clinical condition of the patient into account, deﬁnes the dis-
ease as mild, moderate, or severe [14]. This scale has been
shown to correlate better with survival of the affected
patients. For this reason, we chose to use this 3-grade scale
in our study.
In this single-center study, we evaluated predisposing
factors for the development of moderate-to-severe chronic
GVHD in 679 consecutive patients who underwent allo-
geneic HSCT at Huddinge University Hospital. The aim
was to find patients at increased risk of developing more
severe forms of chronic GVHD. These patients may need
more aggressive or prolonged immunosuppressive treatment
and might be included in studies evaluating new treatments,
such as extracorporeal photopheresis [15]. To avoid intro-
ducing bias and to increase the statistical power of the analy-




Among 810 consecutive patients who underwent allo-
geneic HSCT between November 1975 and December
2000, 679 survived more than 3 months and were evaluated
for chronic GVHD. The source of stem cells was bone
marrow (BM) in 561 cases (83%) and granulocyte colony-
stimulating factor (G-CSF) mobilized peripheral blood stem
cells (PBSC) in 118 cases (17%). Patient and donor charac-
teristics are shown in Table 1.
Conditioning and Supportive Care
The majority (369/568 [65%]) of patients with malignant
disease received 10 Gy of total body irradiation (TBI) (lungs
shielded so that the patient received a median of 9 Gy) com-
bined with cyclophosphamide (Cy) 60 mg/kg for 2 consecu-
tive days [16]. As an alternative, some patients (109/568
[19%]) received Cy combined with busulfan (Bu) (4 mg/kg
on 4 consecutive days) [17] or 12 Gy of fractionated TBI
(3 Gy on 4 consecutive days) (54/568 [10%]). In 24 patients
given a T-cell–depleted graft, 6 Gy (2 Gy for 3 consecutive
days) of TLI was given before TBI of 7.5 Gy (lungs shielded
so that the patient received a median of 7 Gy) [18]. Patients
with metabolic disorders were given Cy (2 mg/m2), frequently
(36/44 [82%]) in combination with Bu (80 mg/m2), although
other combinations with TBI have been used [19]. Patients
with severe aplastic anemia (SAA) received Cy (50 mg/kg on
4 consecutive days). Since 1988, this agent has been given in
combination with ATG (2-5 mg/kg) for 2 to 5 days. In SAA
patients with an unrelated donor, Cy was frequently com-
bined with TBI, Bu, or thoracoabdominal irradiation
(TAI)/TLI. Thirty patients received a nonmyeloablative con-
ditioning regimen with 2 Gy TBI in combination with ﬂu-
darabine (30 mg/m2 for 3-5 days) (n = 16), Bu (4 mg/kg for
2 days) in combination with ﬂudarabine (n = 11), or ﬂudara-
bine plus Cy (30 mg/kg for 2 days) (n = 3).
All patients with an unrelated or mismatched related
donor were treated with ATG (2-5 mg/kg per day) or
muromonab-CD3 (OKT-3) (5 mg/d) for 2 to 5 days prior
to transplantation [20]. Before November 1988, all
patients with hematological malignant disease received 8 to
12 mg methotrexate (MTX) or 20 mg cytarabine (Ara-C)
intrathecally (IT) twice before HSCT to prevent central
nervous system (CNS) leukemia. After transplantation, IT
MTX was given from day 32 and every other week until
day 102. After 1988, only patients with acute lymphoid
leukemia, acute myeloid leukemia M4 or M5, or a history of
CNS disease were given this treatment. Patients with previ-
ous CNS disease were given IT treatment until 24 months
after HSCT.
Since 1995, G-CSF has been routinely given to 258 patients
from day +10 until neutrophil engraftment (>0.5 × 10/L).
Ninety-seven patients were given intravenous immune
globulin (IVIG), most as part of a randomized study [21].
GVHD Prophylaxis
Monotherapy with MTX according to the Seattle pro-
tocol was given to 61 patients [22,23]. Forty-eight patients
received cyclosporine (CsA) alone as GVHD prophylaxis [24].
The CsA dose was gradually tapered 6 months after trans-
plantation. One year after HSCT, CsA was discontinued if
Table 1. Patient and Donor Characteristics
Characteristic n
Disease
Acute myeloid leukemia 169 (25%)




Myelodysplastic syndrome 25 (4%)
Chronic lymphoid leukemia 8 (1%)
Myeloma 13 (2%)
Other malignant disease 2 
Solid tumors 17 (3%)
SAA 44 (6%)
Fanconi anemia 6 (1%)
Metabolic disorders 44 (6%)
Disease status
First complete remission/chronic phase 320 (56%)
Second or later remission/chronic phase 176 (31%)
Partial remission 28 (5%)
Not in remission/chronic phase 44 (8%)
Recipient age (range), y 26 (0-77)
Recipient sex, male/female 408/271
Donor age (range), y 33 (0.5-67)
Donor sex, male/female 366/312
Female donor to male recipient 175 (26%)
Nucleated cell dose (range), ×108/kg 2.7 (0.1-80)
Donor
HLA-identical sibling 424 (62%)
HLA-identical parent 11 (2%)
Matched unrelated donor 185 (27%)
Mismatched related donor 28 (4%)
Mismatched unrelated donor 31 (5%)
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no signs of chronic GVHD were found. T-cell–depleted BM
was given to 34 patients by previously described techniques
[18]. Between August 1985 and April 1989, 274 patients
received combination therapy with the ﬁrst 4 doses of MTX
given together with CsA, as described above [18,25,26].
Between May 1989 and January 1995, 77 leukemic patients
were given combination therapy on an individual basis [27].
CsA was tapered after 2 months, if possible, and MTX
was continued until day 102 after HSCT. Since 1995 (n =
157), a short course of MTX in combination with low-
dose CsA has been used [28]. Six patients were given CsA
with prednisolone and 22, CsA combined with mycopheno-
late mofetil.
Diagnosis of GVHD
Both acute and chronic GVHD were diagnosed on the
basis of clinical symptoms or veriﬁed by biopsy (skin, liver,
gastrointestinal tract, or oral mucosa). Acute GVHD was
graded on a scale from 0 (absent) to IV (severe) according to
published criteria [22]. The severity of chronic GVHD was
deﬁned as mild, moderate, or severe. Mild disease included
sicca and minor skin and/or liver symptoms with a Karnofsky
score of ≥90%. Moderate disease involved symptoms from 1
or more organs that were controlled by immunosuppression
but necessitated prolonged or continuous therapy. The
Karnofsky score in these patients ranged from 70% to 80%.
Severe disease was defined as restricted functions, such as
malabsorption, severe bronchiolitis, and sclerosis of the skin
with Karnofsky score less than 70% [1,13,14]. The severity
of chronic GVHD was classiﬁed by the treating physician.
Grading was according to what we report to the interna-
tional bone marrow transplantation registry (IBMTR) as
“overall total severity.”
Treatment of GVHD
Acute GVHD grade I was treated with prednisolone
2 mg/kg per day. After 1 week, the dose was gradually
tapered, if possible. In more severe cases, ATG, methylpred-
nisolone, MTX, and/or PUVA were given. Several strategies
were used to treat extensive chronic GVHD, including
prednisolone, CsA, prednisone on alternate days [29], aza-
thioprine [30], PUVA [31], thalidomide [11], TLI [32], and,
more recently, extracorporeal photopheresis [12].
Cytomegalovirus Infection, Reactivation, and Disease
Before 1988, cytomegalovirus (CMV) infection was diag-
nosed by a standard viral culture technique. Between 1988
and 1992 a rapid isolation technique was applied. Serocon-
version also was accepted as a sign of infection. After 1992,
patients in whom CMV DNA was detected in 2 consecutive
leukocyte-based semiquantitative polymerase chain reaction
(PCR) tests, although not fulﬁlling criteria for CMV disease,
were given the diagnosis of CMV infection/reactivation. In
all cases of CMV disease, the diagnosis required relevant
clinical symptoms from affected organs and, with the excep-
tion of retinitis, proof of CMV from the affected organ [33].
Statistical Analysis
Results were analyzed as of January 21, 2002. Time to
development of moderate-to-severe chronic GVHD was
used to calculate the cumulative probability curves (Kaplan-
Meier method). Death or relapse was a censored observation,
unless moderate-to-severe chronic GVHD was present [34].
Comparisons were made with the log-rank (Mantel-Haenszel)
test [35]. Mild chronic GVHD was not considered an event.
In patients who had relapses, grade of chronic GVHD before
the relapse and subsequent donor leukocyte infusion treat-
ment was used. The Cox proportional hazard regression
model was used for univariate and multivariate analyses [36].
Only patients surviving at least 90 days after HSCT, and
therefore at risk of development of chronic GVHD, were
included in the analyses. Thirty potential risk factors for
chronic GVHD were studied (Table 2). Only factors at
≤10% levels in the univariate analyses were introduced into
the stepwise elimination multivariate analyses. This analytic
approach is designed to generate predictive factors for moderate-
to-severe chronic GVHD, not causality.
Patients given monotherapy with MTX or CsA were
grouped together, because they had the same incidence of
acute and chronic GVHD [24]. For the same reason,
patients receiving T-cell–depleted grafts were grouped with
those receiving combination therapy with CsA and MTX as
GVHD prophylaxis [18]. A female donor was considered
immunized if she had been pregnant or had undergone
blood transfusion. Patients with malignant disease in first
complete remission or ﬁrst chronic phase and all with non-
malignant disorders were considered as having early disease.
All others were considered as having late disease. Bidirec-
tional ABO mismatch means blood group A to B or B to A.
Administration of G-CSF was analyzed as a potential risk
factor because we have found a higher incidence of acute
GVHD grades II to IV in patients receiving G-CSF after
HSCT (unpublished data). In patients with CMV infection
and moderate-to-severe chronic GVHD, the CMV infec-
tion always preceded the GVHD. The cumulative probabil-
ity curves for survival and relapse-free survival were calculated
with the Kaplan-Meier method. Censored observations
were taken into account.
RESULTS
Incidence of Chronic GVHD
Among the 679 patients, 279 developed chronic GVHD
(223 mild, 41 moderate, and 15 severe). The overall cumula-
tive probability of presence of chronic GVHD at 5 years was
50%; the probability was 10% for moderate-to-severe dis-
ease (Figure 1).
Risk Factors for Moderate to Severe Chronic GVHD
In Cox regression univariate analysis, 5 factors were
significant at the (5% level (Table 2). These factors and
2 additional ones at the 5% to 10% level were included in
the subsequent stepwise elimination multivariate analysis.
Significant risk factors for moderate-to-severe chronic
GVHD are shown in Table 3a. If CML was excluded from
the multivariate analysis, recipient age was also statistically
signiﬁcant (Table 3b). The analysis was corrected for year of
transplantation. The cumulative probability of moderate-to-
severe chronic GVHD in patients with previous acute
GVHD grades II to IV was 17%, compared with 8% in
those with acute GVHD grades 0 to I (P = .004) (Figure 2).
The probability of development of moderate-to-severe
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chronic GVHD increased with increasing severity of acute
GVHD. The cumulative probability was 6% for those with
no previous acute GVHD, 8% for those with grade I
GVHD, 16% for those with grade II, and 44% for patients
with previous acute GVHD grade III. The cumulative prob-
ability of severe chronic GVHD was 1%, 2%, 4%, and 24%
for patients without and those with grade I, grade II, and
grade III acute GVHD, respectively. Among patients with
CML, the probability of moderate-to-severe chronic GVHD
was 17% compared with 7% for patients with other diag-
noses (P < .001) (Figure 2). In male recipients with an immu-
nized female donor the probability of moderate-to-severe
Table 2. Univariate Analysis of Risk Factors for Moderate-to-Severe Chronic GVHD in 679 HSCT Patients
Factor 0/1 n Relative Hazard P
Recipient age <18 y/≥18 y 248/431 2.31 .01*
Donor age <18 y/ ≥18 y 149/524 2.41 .04*
Female donor to male recipient No/yes 501/175 1.49 .17
Immunized female donor to male recipient No/yes 595/81 2.29 .01*
HLA-identical sibling No/yes 435/244 0.89 .69
Unrelated donor No/yes 216/463 1.23 .50
Malignant disease No/yes 94/585 1.26 .57
CML No/yes 518/161 2.54 <.001*
Disease stage Early/late 406/273 1.09 .74
Nucleated cell dose Continuous Variable 0.96 .30
Cell source BM/PBSC 561/118 1.05 .88
Conditioning TBI/Bu 533/146 1.21 .55
GVHD prophylaxis Mono/comb 109/570 1.23 .59
Splenectomy No/yes 653/26 0.49 .48
ATG during conditioning No/yes 426/253 0.74 .31
ABO minor mismatch No/yes 543/133 0.85 .66
ABO major mismatch No/yes 528/148 1.54 .14
ABO bidirectional mismatch No/yes 645/31 1.27 .39
G-CSF after HSCT No/yes 421/258 0.61 .10
IVIG after HSCT No/yes 581/97 0.87 .73
Acute GVHD 0/I-IV 183/496 1.82 .09
Acute GVHD 0-I/II-IV 553/126 2.41 .003*
CMV reactivation No/yes 371/308 1.26 .40
CMV disease No/yes 630/49 1.79 .18*
Recipient herpes virus serology† 0-2/3-4 154/496 1.42 .31
Donor herpes virus serology† 0-2/3-4 183/407 1.32 .43
Recipient CMV serology Neg/pos 185/475 1.25 .51
Donor CMV serology Neg/pos 256/353 1.09 .78
CMV-positive recipient and donor No/yes 319/287 1.09 .83
CMV-negative recipient and donor No/yes 493/106 1.12 .78
HSCT year Continuous Variable 0.98 .28
*Factors included in the multivariate analyses.
†Seropositivity for 0 to 2 versus 3 or 4 herpes viruses (CMV, herpes simplex virus, varicella zoster virus, Epstein-Barr virus).
Figure 1. Cumulative probability of overall and moderate-to-severe chronic GVHD in 679 long-term survivors of HSCT.
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chronic GVHD was 17% compared with 8% in all others
(P = .01). Children (<18 years) had a lower probability than
adults, 5% and 12%, respectively (P = .01).
The incidence of moderate-to-severe chronic GVHD
increased with an increasing number of risk factors (acute
GVHD, CML, and immunized female donor to male recipi-
ent). If no risk factors were present, the cumulative probabil-
ity was 5%, with 1 risk factor it was 13%, with 2 it was 23%,
and with all 3 risk factors present it was 45% (Figure 3).
To answer who needs more aggressive treatment after
the development of chronic GVHD, we performed an
analysis of predictive factors for moderate-to-severe chronic
GVHD versus mild disease among all patients who devel-
oped chronic GVHD (n = 279). We found the presence of
grade II to IV acute GVHD (relative hazard [RH], 2.18;
95% CI, 1.23-3.86; P < .01) was the only predictive factor
for moderate-to-severe chronic GVHD among patients who
developed chronic GVHD.
Figure 2. The cumulative probability of moderate-to-severe chronic GVHD in 679 long-term survivors of HSCT in the presence or absence (uni-
variate comparison) of the 4 signiﬁcant risk-factors. A, Acute GVHD (aGVHD) grades II to IV or grades 0 or I. B, Patients with CML or other dis-
ease. C, Recipient age <18 or ≥18 years. D, With or without immunized female donor to male recipient.
Table 3a. Multivariate Analysis of Risk Factors for Moderate-to-Severe
Chronic GVHD in 679 HSCT Patients*
Factor RH 95% CI P
Acute GVHD II-IV 2.30 1.29-4.10 .005
CML 2.37 1.38-4.08 .002
Immunized female donor 2.16 1.14-4.11 .02
to male recipient
Table 3b. Multivariate Analysis with CML Omitted from the Analysis*
Factor RH 95% CI P
Acute GVHD II-IV 2.61 1.46-4.66 .001
Recipient age ≥18 y 2.42 1.23-4.77 .01
Immunized female donor 1.95 1.02-3.74 .04
to male recipient
*Adjusted for year of transplantation.
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Survival and Disease-Free Survival
The best overall survival and disease-free survival (DFS)
were seen in patients with mild chronic GVHD (Figures 4
and 5). In patients with moderate chronic GVHD, survival
and DFS were no better than in patients without chronic
GVHD. Patients with severe chronic GVHD, however, had
very poor survival and DFS rates (Figures 4 and 5).
DISCUSSION
In this study we used a 3-graded scale for classiﬁcation
of chronic GVHD that was based on mild/moderate/severe
clinical impression [14]. This system appears to be the most
predictive, but it has some limitations. In the absence of
objective criteria, reproducibility, reliability, and validity are
questionable. These classiﬁcations also may reﬂect a lengthy
period of observation. However, at our center all classiﬁca-
tions of chronic GVHD have been made by a very small
number of physicians using similar criteria for classiﬁcation.
All previous studies of risk factors for chronic GVHD
analyzed chronic GVHD in general, regardless of severity.
However, the severity of chronic GVHD markedly affects
outcome. For example, mild chronic GVHD has a beneﬁ-
cial effect on survival in patients with leukemia because of
the GVL effect [8-10]. In this study, the best long-term
survival and DFS rates were seen among patients with mild
chronic GVHD (Figures 4 and 5). In patients with moderate-
to-severe chronic GVHD, survival was worse than in
patients with mild GVHD or without chronic GVHD. We
found no difference in relapse rates between patients with
Figure 3. The cumulative probability of moderate-to-severe chronic GVHD in patients with 0 to 3 signiﬁcant risk-factors (RF) present according
to Table 3a.
Figure 4. Probability of survival among 679 patients without or with mild, moderate, or severe chronic GVHD after HSCT. Left truncated sur-
vival curves are presented. The number of patients at risk at 1, 3, 5, and 10 years in the different groups is shown to the left of the ﬁgure.
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more severe chronic GVHD and those with mild disease,
so there is probably not a stronger GVL effect in more
severe disease.
Because moderate-to-severe chronic GVHD is disabling
for the patient and is not associated with improved survival,
it is a complication that should be prevented. One must
therefore detect risk factors for moderate-to-severe disease
rather than those associated with any degree of GVHD.
Whether more aggressive or prolonged immunosuppressive
treatment can prevent or modulate severe chronic GVHD is
controversial. Results of some studies have shown satisfac-
tory results with extracorporeal photopheresis [12,15,37].
We found that patients with previous acute GVHD
grades II to IV run a higher risk of developing more severe
chronic GVHD. Among patients who developed chronic
GVHD, previous acute GVHD grades II to IV was the only
predictive factor for development of moderate-to-severe
versus mild disease. Many other studies have shown that
acute GVHD is a risk factor for the development of chronic
GVHD [5-7,38,39). One could therefore assume that more
severe forms of acute GVHD may lead to more severe
forms of chronic GVHD. In this study the risk of more
severe chronic GVHD increased with increasing grade of
acute GVHD, especially in patients with previous acute
GVHD grade III. After HSCT, thymus function is nega-
tively affected by various factors, such as conditioning with
chemotherapy and/or irradiation, use of corticosteroids, and
acute GVHD [40-42]. Conditioning before HSCT leads to
decreased stromal production of interleukin-7 and conse-
quent blocks in the maturation of thymocytes. Acute
GVHD is mainly caused by activated alloreactive T-cells
that produce substantial organ destruction, whereas chronic
GVHD clinicopathologically has more autoimmune fea-
tures [1,2]. Therefore it is possible that a damaged thymus,
which has decreased capability of negative T-cell selection,
will release more autoreactive T-cells and that this process
would lead to more chronic GVHD with autoimmune simi-
larities [43]. In patients with more severe acute GVHD
(grades II-IV), the thymus is probably more damaged than
in milder forms, both by GVHD itself and by the additional
treatment these patients receive [1,40-42].
Another factor that affects thymus function is age. In
older patients thymus function deteriorates. The decline in
function, with the conditioning therapy and corticosteroid
treatment, may put older patients at a higher risk of chronic
GVHD. Many other studies have shown age to be associated
with all degrees of chronic GVHD [5-7,38]. Because most
patients with CML are adults, age and presence of CML
may interact with each other in the multivariate analysis. For
this reason we performed analysis with and without CML. In
this study we also found that if CML was excluded, there was
a correlation between older recipient age and the develop-
ment of moderate-to-severe chronic GVHD. Others investi-
gators have reported a correlation between donor age and
the development of chronic GVHD [5,6]. Donor age was
signiﬁcant in the univariate but not in the multivariate analy-
sis. However, donor and recipient age often correlate with
each other, at least for sibling donors [6].
The diagnosis of CML was a significant risk factor in
the multivariate analysis. This factor previously has been
shown to correlate with the presence of chronic GVHD of
any grade [38]. Patients with CML usually are above the
mean age for HSCT, and in that respect they are at
increased risk of chronic GVHD. Many patients with CML
have been given interferon as maintenance treatment before
transplantation. Interferon has a well-known immune stim-
ulatory effect with up-regulation of HLA class II cell surface
molecules [44]. Whether this effect inﬂuences the develop-
ment of both acute and chronic GVHD is still unknown and
needs to be further studied. Some studies have found a cor-
relation between interferon treatment before HSCT and
development of GVHD, whereas others have not [45-48].
At our center, we have seen a lower risk of leukemia relapse
in patients with CML than in those with acute leukemia
[49]. This finding may be due to the higher incidence of
chronic GVHD among the CML patients.
Figure 5. Probability of DFS among 568 patients with malignant disease without or with mild, moderate, or severe chronic GVHD after HSCT. Left
truncated DFS curves are presented. The number of patients at risk at 1, 3, 5, and 10 years in the different groups is shown to the left of the ﬁgure.
Risk Factors for Moderate-to-Severe Chronic GVHD
681B B & M T
A previous study from the IBMTR by Gale et al [50]
showed that transplantation from an alloimmune female
donor to a male recipient was the strongest predictor of
development of acute GVHD. This risk factor has been
reported signiﬁcant for de novo chronic GVHD [6], and the
ﬁnding was conﬁrmed in our study. A graft from a female
donor may contain, through previous pregnancies or trans-
fusions, activated alloreactive T-cells against the male minor
histocompatibility antigen H-Y [51].
A previous study from our center showed a correlation
between CMV infection and development of chronic
GVHD [52], but a more recent report showed no such cor-
relation [39]. An experimental study showed a correlation
between CMV infection and development of severe chronic
GVHD [53]. This ﬁnding was not conﬁrmed for moderate-
to-severe disease. An explanation of the difference between
this ﬁnding and previous ﬁndings from our center may be
that in the current analysis risk factors for moderate-to-
severe disease were evaluated, whereas in the other study
any grade of disease was analyzed. In addition, the methods
of CMV diagnosis have changed with time. In more recent
years, diagnosis based on PCR results has been used. This
assay detects CMV DNA, but the presence of the DNA
does not necessarily mean that protein synthesis occurs.
We found that previous acute GVHD grades II to IV,
higher patient age, CML diagnosis, and transplantation
from an immunized female donor to a male recipient were
independent predisposing factors for the development of
moderate-to-severe chronic GVHD. Among patients who
developed chronic GVHD, acute GVHD grades II to IV
was the only factor associated with moderate-to-severe
chronic GVHD versus mild disease. These data may be used
to identify patients who may need more aggressive immuno-
suppressive protocols, possibly new treatments such as
extracorporeal photopheresis. Prospective randomized trials
of prolonged immunosuppression or additional treatment at
the onset of early chronic GVHD may be conducted with
patients with 2 or more risk factors for moderate-to-severe
chronic GVHD.
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